The Novigenix AI-driven RNA platform offers precise & predictive immune response profiling for better patient outcomes.
The immune system is key to our health and essential for both cancer surveillance and treatment. Using AI and RNA sequence analysis, Novigenix captures the cancer immunity cycle during the multi-stage disease progression and response to therapy. Novigenix has a proven track record with best-in-class blood test on the Swiss market for early detection of colorectal cancer. Using its proven LITOSeek™ platform, Novigenix offers solutions for biopharma companies in drug development and drug target discovery to enable more effective therapeutics, and faster time to market for better patient outcomes.
Delivering data for better care across the patient journey
Precise data
The cancer patient´s journey is invariably complex and can have severe side effects from different treatments. Even at today’s advanced stage of medicine, cancer patients often struggle to understand how severe their cancer is, and how to best treat it. There is a gap in precise information to guide therapy development and clinical decision making.
By comprehensively analysing the patient`s blood RNA and systemic immune response signatures, Novigenix contributes to closing this gap. We develop precise information about the risk and the stage of cancer, and likely response to immunotherapy.
Predictive data
In many indications, doctors cannot yet consistently prescribe the right treatment due to the heterogeneity of both the molecular cancer entities and the patient population, let alone anticipate the development of a cancer which is invariably complex.
Access to large amounts of accurate patient data combined with state of the art of computational systems capacity enable predictive biomarker discovery and development, as well as validation of biomarkers that can be applied in novel therapy development, new drug target discovery, ultimately improving patient journey.
Innovative profiling
New advances in identifying biomarkers to understand the highly dynamic interplay between the immune system and cancer will dramatically improve our understanding of heterogeneity of patient response to therapeutic intervention, and catalyse the conversion of cancer into a manageable chronic disease.
The immune system is crucial for the patient`s response to cancer as well as to different therapeutic modalities, and it is itself has been the target of revolutionary new immunotherapy of cancer over the past decade. By understanding the immune response profile, we can significantly enhance efficient development of effective therapies and ultimately improve patients´ experience and the success of their therapeutic journey.
How we do it
